The largest database of trusted experimental protocols

2 protocols using anti cd34 percp

1

Immunophenotypic Analysis of Leukemia Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood samples and bone marrow aspirate for immunophenotype analysis was obtained prior to plerixafor administration on day -5 and after its administration on day -4 (prior to thiotepa administration). The cell content was phenotyped by flow cytometry using BD FACSCanto™ II flow cytometer, BD FACSDiva 6.0 software, and a red cell lysis/multi-color antibody protocol. The following monoclonal antibodies against cell surface or intracellular markers were used: Anti-CD45 APC-H7 (Clone 2D1), Anti-CD33 PE-Cy7 (Clone P67.6), Anti-sCD3 V450 (Clone UCHT1), Anti-CD7 FITC (Clone M-T701), Anti-CD5 PE-Cy7 (Clone L17F12), Anti-CD19 APC (Clone SJ25C1), Anti-CD33 APC (Clone P67.6), Anti-HLADR APC-H7 (Clone L243), Anti-CD184 (CXCR4) PE (Clone ID9), Anti-IgG 2a PE (Clone X-39; all 6from BD Biosciences, San Jose, CA); Anti-CD34 PerCP (Clone 581), Anti-cCD3 PerCP (Clone SK7; all from Biolegend, San Diego, CA); Anti-CD38 FITC (Clone T16; Beckman Coulter, Pasadena, CA) and Anti-CD133 APC (Clone AC133, Miltenyi Biotec, Cambridge, MA). Patient-specific combinations of 6 or 8 antibodies and Boolean gating scheme were used to identify the blasts for each patient and determine their CXCR4 expression. Matched isotype control was used to determine the upper limit of fluorescent background.
+ Open protocol
+ Expand
2

Characterization of Daratumumab Binding

Check if the same lab product or an alternative is used in the 5 most similar protocols
Daratumumab was from Janssen Pharmaceuticals (Titusville, NJ), isotype control (human IgG1 kappa) from Sigma-Aldrich (St Louis MO), and anti-CD38-APC, anti-CD34-PerCP, anti-CD59-FITC (H19 clone) and isotype controls from BioLegend (San Diego, CA). Second antibody for Daratumumab binding was mouse anti-human IgG Fc APC-conjugated (HP6017, BioLegend). The anti-C1q was a rabbit polyclonal FITC-conjugated (Abcam, Cambridge, MA) used with an appropriate isotype control. BRIC 229, a CD59 neutralizing antibody, was obtained from the International Blood Group Reference Laboratory of the Bristol Institute for Transfusion Sciences (NHS Blood and Transplant, Bristol, UK), and the anti-CD46 monoclonal GB24 was kindly provided by Dr. J. Aktinson, Washington University, St. Louis, MO, USA. Antibodies were titrated for optimal use and analyses performed on a BD Accuri flow cytometer (BD Biosciences, San Jose, CA).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!